Abstract
P-glycoprotein (P-gp), a cell membrane protein, has been found in multidrug-resistant cancer cells. A total of 104 smears from patients with breast-cancer-associated pleural effusions and ovarian-cancer-related peritoneal effusions were studied for P-gp with the antibody C-219 and the avidin-biotin-immunoperoxidase method. Samples were taken before and 3 and 7 days after intracavitary bleomycin therapy and reaccumulation of effusion was assessed at 30 days. Smears that were P-gp-negative by the 7th day were associated with a good 30-day response to bleomycin in the majority of cases, while P-gp-positive smears were associated with a significant reaccumulation of fluid at 30 days. P-gp status is a valuable prognostic indicator of response to intracavitary bleomycin treatment in effusions from breast or ovarian cancer.
MeSH terms
-
ATP Binding Cassette Transporter, Subfamily B, Member 1 / metabolism*
-
Adenocarcinoma / drug therapy*
-
Adenocarcinoma / metabolism
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Ascitic Fluid / drug therapy
-
Ascitic Fluid / metabolism
-
Bleomycin / administration & dosage
-
Breast Neoplasms / drug therapy*
-
Breast Neoplasms / metabolism
-
Cyclophosphamide / administration & dosage
-
Doxorubicin / administration & dosage
-
Exudates and Transudates / metabolism*
-
Female
-
Fluorouracil / administration & dosage
-
Humans
-
Immunohistochemistry
-
Methotrexate / administration & dosage
-
Ovarian Neoplasms / drug therapy*
-
Ovarian Neoplasms / metabolism
-
Pleural Effusion / drug therapy
-
Pleural Effusion / metabolism
Substances
-
ATP Binding Cassette Transporter, Subfamily B, Member 1
-
Bleomycin
-
Doxorubicin
-
Cyclophosphamide
-
Fluorouracil
-
Methotrexate